Toggle navigation
Home
Search
Services
Blog
Contact
About
OBl-1 - 201: Dosing regimen, cogential hemophilia, non-life threatening bleeding
Bergman, Garrett E.
Octagen Corporation, Blue Bell, PA, United States
Search 11 grants from Garrett Bergman
Search grants from Octagen Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Oral and Craniofacial Bone Regeneration using MicroRNA Modulation
Muscle Plasticity Training /Detraining in Older Adults
Neural Net & Ai Software
Peritoneal Macrophage Migration in Endometriosis
Effects of OMEGA-3 Fatty Acids on Lipid Transport
Recently added grants:
Structure and Mechanism of G-proteins and cell adhesion proteins in regulation of cell growth and motility
Modulation of Protein Biogenesis and Secretion by Natural Product Translocon Ligands
Molecular and cellular mechanisms regulating actin dynamics
Inflammatory mechanisms responsible for the development of multiple organ dysfunction in pediatric patients following allogeneic blood and marrow transplantation (BMT).
Fluorescence tools that illuminate biology and inspire translation
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44HL064497-04
Application #
7149838
Study Section
Special Emphasis Panel (ZRG1)
Project Start
2005-08-01
Project End
2008-07-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2005
Total Cost
Indirect Cost
Institution
Name
Octagen Corporation
Department
Type
DUNS #
052982852
City
Blue Bell
State
PA
Country
United States
Zip Code
19422
Related projects
Comments
Be the first to comment on Garrett Bergman's grant